Stay updated with breaking news from Haystack Sciences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- The "DNA Encoded Library: Platforms and Services Market (2nd Edition), 2023-2035" report has been added to ResearchAndMarkets.com's offering....
/PRNewswire/ -- Roots Analysis has announced the addition of "DNA Encoded Library Market, 2023-2035" report to its list of offerings. Owing to its access to...
GEN’s first-ever A-List for synthetic biology ranks the five largest public companies by their 2020 revenues, and the five largest private companies by the total capital they have raised.
Article content A machine learning start-up that is aiming to speed up drug discovery and shake up the pharmaceutical industry has raised US$400 milllion from investors including, the Canadian Plan Investment Board, SoftBank and Temasek. Insitro, which is run by former Stanford artificial intelligence professor Daphne Koller, has partnerships with Gilead Sciences and Bristol-Myers Squibb to discover new biological targets for drug treatments, and the drugs themselves. We apologize, but this video has failed to load. Try refreshing your browser, or CPPIB leads group investing $400-million in ...
Share insitro, an artificial intelligence drug discovery startup, has added a $400 million Series C round to its already impressive fundraising haul. The financing is set to close during the first full week of April, according to the company. Canadian Pension Plan Investment Board led the raise, which also included a laundry list of participants. These names include: Andreessen Horowitz, funds and accounts advised by T. Rowe Price Associates, Casdin Capital and funds and accounts managed by BlackRock, ARCH Venture Partners, Foresite Capital, GV, Third Rock Ventures, Two Sigma Ventures, HO...